• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds of formula (I): <IMAGE> +TR <IMAGE> wherein Z1 and Z2 are the same or different and each represents a methylenedioxy substituent, or up to three methoxy substituents; R2 and R3 are the same or different and each is alkyl having 1-3 carbon atoms, prop-2-enyl or prop-2-ynyl; R4 and R5 are the same or different and each is a benzyl or phenethyl group wherein the phenyl ring is optionally substituted by one or more of halogen, alkoxy having 1 to 3 carbon atoms and methylenedioxy; A and B are the same or different and each is an alkylene radical containing 1,2, or 3 carbon atoms; L is an alkylene chain having from 2 to 12 carbon atoms or is a group -L1.0.L2- wherein each of L1 and L2 is alkylene having at least two carbon atoms and taken together L1 and L2 having up to 11 carbon atoms; and X- is an anion; may be used to effect neuromuscular paralysis in mammals.
    公开号:SU718008A3
    申请号:SU762428001
    申请日:1976-12-09
    公开日:1980-02-25
    发明作者:Бедфорд Стенлэйк Джон；Дэвид Вэйг Роджер；Генри Дьюэр Джорж；Эрвин Джон；Чандра Дхар Нирмал
    申请人:Дзе Велкам Фаундейшн Лимитед (Фирма)；
    IPC主号:
    专利说明:

    (54) METHOD OF OBTAINING IZOHINOLINE DERIVATIVES
    one
    This invention relates to methods for the preparation of nzoughquinoline derivatives.
    A number of isoquinline derivatives possessing biological activity 1 are known.
    In the preferred way, new nzoquinoline derivatives are obtained that possess biological activity.
    A method for producing isoquinoline derivatives of the general formula is provided.
    concluding that the di-tertiary base of the general formula
    NACOOLOCOBN
    3Kij
    de A, B, L, Pz, R4 / i or Zj have the indicated meanings, or the corresponding monotretichny base in which one of the isoquinoline groups is substituted in position 2 by the RJ or PZ group, is quaternized with a reactive ester derivative of the general formula, -,
    RsOHilil
    where RS is R or RS. Preferably, toluenesulfonic acid methyl ester or benzenesulfonic acid methyl ester, which is taken in molar excess, is used as a compound of the general formula w, and the process is carried out in a solvent such as alkanol, aromatic hydrocarbon, chlorinated hydrocarbon or aliphatic ketone, in the temperature range from room temperature to temperature. boiling solvent. The process can be carried out in the dark or under pressure;
    Example. 0.2 mol of acryloyl chloride in 60 ml of dry benzene is added over 0.5 h with mechanical displacement to 0.1 mol of pentane-1,5-diol, 0.2 mol of triethylamine and 0.1 g of pyrogallol in 100 ml of dry benzene . Approximately 100 ml of dry benzene is then poured, then 10 ml of triethylamine and the mixture is stirred at 50 ° C for 0.5 h. Hydrochloric triztilamine is filtered off and the solvent is removed under vacuum, a yellow oil remains, which is distilled in the presence of traces of p-methoxyphenol c, 12.9 g of diacrylate of 1,5-pentamethylene (61%) are obtained, t.x1.90954 / 0, 01 mm Hg. Art.
    A solution of 4.43 g of tetrahydropapaverine and 1.30 g of 1,5-pentamethylene diacrylate in 15 ml of dry benzene is stirred at reflux for 18 h in the dark. The solvent is removed in vacuo and the remaining light red oily residue is dissolved in chloroform (10 ml). Approximately 400 ml of ether is added, then approximately 50b ml of a saturated ethereal solution of oxalic acid is obtained, a white flocculent precipitate is obtained, which is filtered off, washed with ether, and i.e. Double crystallized from ethanol to obtain 3.5 g of a white powder of N, N-4,10-OTOKca-3, l 1-dioxotridecylen-1, 13-bis-tetrahydropapavena (51%, m.p1 1.1ni) daoxalate.
     The free base, N, N-4,10-dioxa-3, 11-dioxotridecylen-1,13-bis-tetrahydropapaverine, is obtained by basifying an aqueous solution of dioxalate with sodium bicarbonate solution, followed by extraction with toluene and evaporation of the solvent (colorless viscous oil).
    Carefully dried base (0.5 g) in spectroscopically pure acetonitrile (8 ml) is treated with 8 ml of methyl iodide at room temperature for 22 hours. The filtered reaction mixture is added dropwise to about 450 ml of filtered dry ether with mechanical stirring. A flocculent white precipitate is filtered off, washed with dry ether and dried in vacuo ie over PjOs at 50 ° C. The diiodide M, M-4DO-dioxa-3,11-dioxotridecylen-1, 13 ms-tetrahydropapaverini is obtained, m.p. 143148С with softening at 138 ° С.
    Using the above method, but replacing the iodide with methyl methyl ether of methoxulphonic acid, methyl esters of benzolsulfonic acid, toluenesulfonic acid, naphthalene-1-sulfonic acid and naphthalene-2-sulfonic acid and conducting the reaction within 48 hours rather than 22 hours, the following salts are obtained:
    M, M-dimetsh-1, M-4, 10-diox-3,11-dioxotridedelen-1, 13-bms-tetrahydropapaverinovydl mesylate; white powder, t. pl. 104-112 ° C;
    M, M-dimethyl-M, M-4DO-dioxa-3,11-dioxotridedelen-1, 13-5is-tetrahydropapaverine-dibenzylate, white powder, t. Pl. 85-90 ° C; softened at 60 ° C;
    N, N-dimethyl-N, N-4, 10-dioxa-3, 11-dioxotridecylen-1, 13-bis-tetrahydropapaverinium-ditoeilate, white powder; t. square 70-90 ° C;
    M, M-dimesh1-M, N-4,10-diox-3,11-dioxotridedelen-1, 13-bis-those rahidropapaveriniy-dinaph-Ysylate, light yellow powder, so pl. 6585 ° C;
    N, N .dimethyl-M, N-4,10-diox-3,11-dioxotridedelen-1, 13-bms-tetrahydro-para-para-dynaph-2-silat, white powder, t. Pl. 60-80 ° C.
    Example 2. According to a procedure similar to that described in Example 1, the following tertiary bases are synthesized via the corresponding oxalate salts:
    i, N-4, 10-dcocca-3, l b-Dioxotride-1.13-bys-D- (-) - tetrahydropapaverine, a colorless, viscous oil, and about 23.5-53.62 ° (with 1.408 in chloroform) ;
    N, N-4, 10-dioxa-3, II-dioctobenzien-1.13-b "c-1- (+) - tetrahydropapaverine, colorless viscous oil, + 62.65 ° (from 0.961 in chloroform);
    N, N-7-methyl-4,10-dioxa-3, l 1-dioxotridedelen-1, 13 - ("s-tetrahydropapaverine;
    N, N-4,10-diox-3,11 - dioxotridecylen-1,13-bis-1, 2, 3, 4-tetrahydro-b | 7-dimethoxy-1 (3, 4-dimethoxyphenyl) Ethyl isoquinoline, colorless in SSC; butter; N, N-4, 11 - dioxa-3,12-dioxotetradecylen-1, 14-bys-tetrahydropapaverine; M, M-4,9-diox-3,0-dioxododecylen-1.12-b cc- (±) -tetrahydropa-taverine, a colorless solid, so pl. 44-46 ° C; N, N-4,9-dioxa-Z. U-dioxododecyleN1,12-bis-D - (-) -tetrahydropapaverine, colorless solid, t, pl. 47-49 ° C, 70, 6 (with 0.395 in chloroform); S, M-4,9-diox-3,10-dioxododecylen-1.12-b MS-i- (+) - tetrahydropapaverine, a colorless solid or solid, so pl. 48-50 ° C; N, N-4,8-dioxa-3,9-dioxodecylen-l, l-bw -tetrahydropapaverine, colorless solid, so pl. 46-48 ° C; N, N-4,7-dioxa-3,8-dioxodecylen-1, 10-5i-1, 2, 3, 4-tetrahydro-6, 7; -dimethoxy-1- (3 4,5 -trimethoxybenzyl) isoquinoline , colorless solid, so pl. 46-47 ° C; N, N-4,7-dioxa-3,8-dioxodecylen-I, 10-bis-1, 2,3,4-tetrahydro-6,7-dimethoxy-1 - (,., Bromo-4,5 - dimethoxybenzyl) isoquinoline, a colorless solid, so pl. 65-67 ° C; N, N-4,7-dioxa-3,8-dioxodecylen-1, 10-b "c-1, 2,3,4-tetrahydro-6,7-dimethoxy-1- (3,4 methylenedioxybenzyl) isoquinoline, colorless solid, so pl. 44-46 ° C; S, M-4,7-diox-3,8-dioxodecylen-, Q-6uc-1, 2,3,4-tetrahydro-6,7-dimethoxy-1- (3 A-dichlorobenzyl) isoquinoline, colorless substance pl. 45-48 ° C; N, N-4,7-diox-3,8-Dioxodecylen-1,10-bis-G, 2,3,4-tetrahydro-6,7-dimethoxy-1- (2,5 dimethoxybenzyl) isoquinoline, colorless hard Doo substance, so pl. 44-46 ° C, from which were obtained the corresponding with and the general formula 1, namely: N, N-dimethyl-N, N-4,10-dioxca 3, ll-dioxo-tridecylen-1, 3-bis-D- (-) - tetrahydropapaverine-dimesylate, so pl. IIO-IH C with softening at 95-97 ° C, 41.67 ° (c 1.323 in chloroform); N, N-dimethyl-N, N 4,10-diox-3,11-dioxotridedelen-1, 13-bis-L- (+) -tetrahydropapernairene-dimesylate, so pl. 110-114 ° C with softening at 95-97 ° C, (+ 40.26 ° (c 1.016 in chloroform); N, N-dimethyl-N, N-7-methyl-4,10-dioxa-3, ll-dioxotridecylen-1, 13-bms-tetrahydropapaverine-dimesylate, white powder, mp 100.5-109 ° C; N, N-dimethyl-N, N-4,10-dioxa-3, II-diocet decylen-1,13-5is-Jg, 2,3,4-tetrapagndo-6,7-dimethoxy-1-l2- (3,4-dimethoxyphenyl) titanium isoquinoline dimesylate, mp 98-105 ° С; N , N-dimethyl-N, N-4, ll-dioxa-3,12-dioxotetradecylen-1, 14-bic-tetrahydro-papavaria Iy-dinodide, mp 132-138 ° C; N, N-dimethyl-N, N-4; lJ-dioxa-3, l 2-dioxotetradecylen-1,14-Tms-tetrahydropane-11I-dimesylate, white powder, mp 109-118 ° C; S, LY: -dimethyl-M, L-4 , 9-dioxa-3,10-dioxo odesh1en-1, 12-bms- (±) -tetrahydropaperine-dimesylate, mp 91-115 ° C; N, N-dimethyl-N, N-4,9-diox-3,10-dioxododecylen-1, 12- (5 "s-D - (-) - tetrahydropapaverine-dimesylate, t, pl. 105-115 ° C, a, 18 ° (from 1.105 in chloroform); M, N-dimethyl-M, Y-4, 9-dioxa-3,10-dioxodecylen-1, 12-6UC-L- (+) -tetrahydropapaverinium-dimesylate, mp 102-113 ° C, a} + 50.28 ° (c 1.093 in chloroform); N, N-dimethyl-N, N-4,8-dioxa-3,9-dioxyco-decylen-1, 11-b is tetrahydropapavernium-dimesylate, white powder, t. square 96-120 ° C; l, N-dimethyl-N, N-4,7-dioxa-3,8-dioxodecylen-1, 10-bis-1, 2,3,4-tetrahydro-6,7-dimethoxy-1- (3,4 , 5-trimethoxybenzyl) isoquinolinium-dimesylate, t. Pl. 123-138 ° C; M, M-dimesh1-y, M-4,7-diox-3,8-dioxodecylen-1, 10 - ("c-1, 2,3,4-tetrahydro-6,7-dimethoxy-1- (2 bromo-4, 5-dimethoxybenzyl) isoquinoline dimesylate, mp 128-140 ° C; N, N-dimethyl-N, N-4,7-dioxa-3,8-dioxidecit en-1 10-bis- 1,2,3,4-tetrahydro-6,7-dimethoxy-1- (3,4-methylenedioxybenzyl) isoquinoline dimesylate, mp 21-132 ° C; l, l l-dimethyl-N, N-4 , 7-dioxa-3,8-dioxodecylen-1, 10-bis-1,2,3,4-tetraparido-6,7-dimethoxy-1- (3,4-dichlorobenzyl) isoquinolinium-dimesylate, so pl. 111-120 ° C; S, M-dimbtil-S, M-4,7-diox-3,8-dioxodecyen-1, G, 2,3,4-tetrahydro-6,7-dimethoxy-1- (2 , 5-dimethoxybenzyl) isoquinoline dimesylate, mp: 86-95 ° C. Example 3. By The method described in example 1 is used to obtain L, L-4,12-dioxa-3,13-dioxopentadecylen-1,15-bcc-tetrahydropapaverine in an excellent viscous oil. 0.5 g of this thoroughly dried compound in 10 ml of chloroform is treated 10 ml of ethyl iodide at room temperature for 22 hours. The filtered reaction mixture was added dropwise to about 50 ml of filtered dry ether with mechanical stirring. A white, flocculent precipitate is filtered off, washed with water with zfir and maintained in vacuum at PjOs at 50 ° C. N, N-dimethyl-N, N-4, l2-dix-3, 13-dioxopentadecylen-1,15-5ms-tetragne; 1opaverinium-diiodide, t. Pl. 114-123 C. Example 4. According to the procedure described in Reamer 3, the following compounds are obtained: N, N-4,13-No.OKca-3,14-flHOKCoreKcanemineH-1, 16-bis — geragiDrpapaverin, viscous oil; N, N-4,7-flHOKca-3,8-AHOKcoflemtrieH-l, 10-5MC- (±) -tetrahydropapaverine, colorless solid, so pl. 47-49 ° C; K1, M-4,7; Diox-3,8-dioxodecylen-1 DO-1,2, heterrahydro-1- (3,4-dimethoxybenzyl) -6, 7-methylenedioxyisoquinoline, colorless solid, so pl. 49-50 ° C; G, M-4,10-diox-3,11-dioxotride (ylen-1,13-bis-1,2,3,4-tetrahydro-1 - (3,4-dimethoxybenzyl) -6,7-metto1epdioxyisoquinoline, colorless viscous oil; M, M-4,7-Dyuks-3,8-Dioxodecylen-1, p-5x-1,2,3,4-tetrahydro-6,7-dimethoxy-1-benznlysohinolin, colorless oil ; N, N- 4,7-lloxa-3,8-dioxodecylen-1,10-bis-11, 2,3,4-tetragvdro-6,7-dlmethoxy-1- (4-methoxybenzyl) yzoquinoline, colorless; oil;; -., lJ-4,7,10-triox-3,11 - daoxotridecylen-1, 13-b is-tetrahydropapaverine, colorless semi-solid, and the corresponding salts of general formula 1, namely: P4, M -dimethyl-1 1, |) -4,13-diox-3,14-di ksogek sadetsilen-1,16-BMS-tetragidropapaversh s-diiodide, ie. pc. 119-123 ° C; S, | M-dimethyl-M, S-4,7-diox-3, 8-dioxodecylen-1, 10-by- (±) -tetrahydropapaver {Sy-diiodo. iiO-BOC; And, M-digiethyl-M, N-4,7-diox-3,8-dioxodecylen-1, 10-bms- (±) -panaveverinium-dimesylate, T.11L.99 .08 ° C (obtained by the method of example 1 ); M, M-dime-gyl-y, 1M-4,7-dioxa-3,8-dioxododelin-1, 10-5is-1,2,3,4-tetrahydro-1- (3, methoxybenzyl) -6, 7:; methylenedioxyisoquinol1111 diodsch, so pl. 144-148 ° C; , M-DNMETHYL, 10-dioxa-3,11-dioxotri decylen-1.13-5ms-1,2,3,4-tetrahydro-1- (3,4-dimethoxybenzyl) -6,7-megilendioxyl gas-quinone -diode | {d, t. pl. 122-129 ° C; N, J-dimethyl-N, N-dioxa-3,8-dioxodecylen-1,10-bms-i, 3,4-tetrahydro-6,7-Dimethoxy-G-benzylisoxJSH-dihydride, t. Pcs. 141l45 ° C ;; l ,,. /;, ..:. - ..,. ., 4, N-4HMeTH T-N, N-4.7-; dioxo-3,8-dioxodecyla-1 LO-by-G, 2,3,4-tetrahydro-6,7-dimethoc-1 - (4-methoxybenzyl) -isoxydyl-diiodide, t. GO1. 143-1 N, M-dimethyl-M, M-4,7,10-trioxa-3,11-dioxo-tridecylen-1,13-tetragy Dropapavernium-diiodide m. Pl. A9-128 ° C. Example 5. The base of N, N-4,7-dioxa-3,8-daoxodecylen-1, (D) - (-) -tetrahydropapaverine, airless solid substance, g.LTL 49 ° cG a - 58.2 ° .. (with G, in chloroform), and the corresponding N, N-dimethyl-N, N-4,7-diox-3,8-dioxodecylen-1,10-by-D - (-) - thetahydropaperulide 1P1Y-dimesylate, t. square 10S-13 ° C, -55.9 (from 0.948 in chlorophore) prepared according to the procedure of Example 1. Then 0.58 g of the base and 5 ml of distilled ethyl ethyl iodide are refluxed in 10 ml of dry benzene for 6 hours. the solid is precipitated; the solution is recrystallized from methanol; the solution is added in drops to 500 ml of dry ether, which is formed by mechatatic transfer. The white flocculent precipitate is filtered off, washed with dry ether and dried in vacuo over PjOs, yielded S, M-dimethyl-M, -4,7-diox-3,8-dioxodecylen-1,10- &amp; c-L- (- ) -tetrahydropapaverine-diiodide, so pl. 122-125 ° C, - 48.9 ° (s - 1.208 in chloroform). Example 6. Using the procedure described in Example 5, N, N-4,7-dioxa-3,8-dioxodecylen-1,10-b "c-L- (+) - tetrahydropapaverine, colorless solid, t pl. 48-50 ° С + 58.9 °; (with 1.021 in chloroform); M, M-d11methyl-M, M-4,7-diox-3,8-dioxodecylen-1,10-bis-L- (-) -tetrahydropapavernium-dimesylate, t. Pl. 105-114 ° C, + 56,4 ° C (from 1.140 in chloroform); N, J-dc-methyl-N, N-4,7-dioxa-3,8-dioxodecylen-1, L- {+) -tetrahydropyridinium-diiodide. + 48.1 (with 1.105 t. Units. 122-126 C, in chloroform). Example 7. 2.07 g of D- (+) -tetrahydropapaverine in dry benzene is added dropwise to 7.66 g of 1,5-pentamethyl 1 di-acrylate in dry benzene and the mixture is refluxed under reflux for 4 hours. vacuum and npOMbiffafoT three times the oily residue with light petroleum ether (b.p. 40-60 ° C). The oily residue is dissolved in benzene and light petroleum ether is added to precipitate the oil. Repeated dissolution in benzene and repeated precipitation with a double volume of light non-trace ether results in a brown oily mass of D - (-) - 1-tetrahydropapaverin-2-yl-4, 10-diox-3,11-dioxotridede-12-ene, - 41.17 ° (from 1.388 in. Chloroform), those of Polygram sil G / UV2S4 in a mixture of ethanol and ethtacetate (1: 1) give one spot with Rf 0.56.1) “ax (C 0 ester) and 1650 cm- (C-CH2). 1.38 g of D- (-) - 1-tetrahydropapaverin-2 -yl-4, 10-diox-3,11-dioxotridedecene and 0.847 g of L - (-) - tetrahydropapavurin are refluxed in dry benzene for 48 hours with constant stirring. The solvent was distilled off, the residue was dissolved in chloroform, and the solution was treated with a saturated solution of oxalic acid in dry ether. The precipitate was recrystallized from ethanol to give Me3p-N, N-4,10-AHOKca-3, l 1-dioxothinenylene-1, 13- (5 "C-tetrahydropapaverine dioxalate, a colorless solid, mp 103-107 ° C ± 0 ° (c 1.183 in water). According to the procedure described in example 1, the free base of Meso-N, N-4.7 is obtained -dioxa-3, 11-dioxotridecylen-P-bms-tetrahydropapaverine, a colorless, viscous oil, (oilijV ± O (from 1.018 in chloroform), and from it meso, Y-4,7-dimethyl-4,10-diox- 3,11- dioxot ridecylen-1, 13- "c-tetrahydropapaverine-dimesylate, mp 102-107 ° C with softening at 9799 ° C, M ± 0 ° (, 335 in chloroform). Example 8. The following compounds were obtained with using the method of example 7 meso-Y, N-4,7-diox-3,8-dioxodecylen-1,10-5is-tetragitsropapaverin, solid resin; meso-N, N-dimethyl-M, N-4,7-diox -3,8-dioxo decilene-1,10-bis-tetrahydropapaverhenium-dimesylate, mp 100-112 ° C ± 0 ° (with 0.409 in chloroform). Example 9. Saturate for 2 hours 36 g of y-butyrolactone and 15.2 g of propanediol-1,3 at 0.5 ° C with hydrogen bromide gas, and then left at 0 ° C for 24 hours. The mixture is added to 300 ml of water and extracted with 2 x 100 ml of dibromoethylene. The combined extracts are washed with water, dried for sodium sulfate and evaporated to give an oil. The main distillation component is about 50 g of 3-bromo-1-bromobutanoate, m.p. 106-140 C / 0.05 mm Hg Art. The viscous bottoms are extracted with petroleum ether (b.p. 60-80 ° C) 3 times 150 ml each time and the combined extracts are evaporated to give a colorless oil, which is propane-1,3-bms- (According to IR) and NMR spectroscopy 4-bromobutanoate). Under reflux, 1.8 g of propane-1,3- &amp; ms- (4-bromobutane6at) in 10 ml of dry toluene is boiled and treated under these conditions.
     ACOOLOCO f
    nGN
    R,
    where Zi and Zj are the same or different, each of which is a methylenedioxy group or up to three methoxy groups;
    RI and Rj, which are the same or different, are alkyl having 1-3 carbon atoms, prop-2-enyl or prop-2-ynyl;
    RE and R4 are the same or different, and each is benzyl or phenethyl, in which the phenyl nucleus can be substituted with odgx (I)
    /
    R
    BAT or several halogens, alkoxy groups having 1-3 carbon atoms, or methylenedioxy groups;
    A and B are the same or different, and each is an alkylene radical containing 1, 2, or 3 carbon atoms;
    权利要求:
    Claims (3)
    [1]
    L is an alkylene chain containing 2-12 carbon atoms, or is a group L, O Lj, where each of LI and Lj is 6, 8-tetrahydropapaverine in 50 ml of toluene, added dropwise within 0.5 hour. The mixture was heated under reflux for 18 hours, cooled and filtered from hydrobromic tetrabromopaverine. The filtrate is evaporated in vacuo and the remaining oil is dissolved in chloroform (10 ml). Approximately 500 ml of ether is added, then approximately 500 ml of a saturated ethereal solution of oxalic acid, a white flocculent precipitate is obtained, which is filtered off, washed with ether and dried. After two recrystallites from ethanol, a white powder of 5,9-dioxa-4,10-dioxotridecylen-1,13-bms-tetrahydropapaverine dioxalate is obtained, mp. 107-115 ° Spo method, described in example 1, receive the corresponding base M, M-5,9-diox-4, 10-dioxotridecylen-1,13-bms-tetrahydropaper-dimesylate, white powder, so pl. 95- 102 ° C, Example 10. 0.8 g of 1,2,3,4 tetrahydro-2- (2-methoxycarbonylethyl) -2-methyl-papaverine-benol sulfonate with a solution of 67.5 mg of pentamethylene glycol and 30 ml of benzenesulfonic acid in 5 ml of methylene chloride is treated. After evaporation of the solvents, the residue is heated on a steam bath under reduced pressure (about 150 ml of mercury) for 24 hours. The final gummy product is dissolved in 25 ml of acetone and slowly added to 250 ml of well stirred ether. The product is a white, slightly sprinkled powder. According to thin layer chromatography, it is N, N-dimetsi-N, l-4, 10-diox-3,11-dioxotridecylen-1,13- (4 with tetrahydropapaverine-dibisilate. Claim 1: A method for producing isoquinolium derivatives the formulas "," -.-.-....... ..:., -) f; 71 is alkylene, and 1 is carbon dioxide, ho is at least two carbon atoms, and when taken together, LI and Lj contain up to 11 carbon atoms; X, is an anion, characterized in that the di-tertiary base of the general formula: NACOOLOCOBN where A, 8, L, Rj, R4: Zi and ZjlHMetoT are Sacheni, ...;. . or the corresponding monotretic Me, whose TV of one of the iguquinoline groups is substituted in position 2 by the Rj or Rj group, is cTa teryneRy with the reaction of the ester derivative of the general formula -. . / RsOH (TH (| where RS is RI or Rj. 2. The method according to claim 1, characterized in that 1 general compound of formula 3 uses methyl toluenesulfonic acid ester or benzenesulfonic acid methyl ester. 3. The method according to claim 1 and 2, characterized in that the compound of the general formula 3 is used in a molar beating and the process is carried out in an environment of a solvent such as an alkanol, an aromatic hydrocarbon, a chlorinated hydrocarbon or an aliphatic ketone. 4. The method according to claims 1, 2 and 3, characterized in that the process is carried out in the temperature range from room temperature to 5. A method according to any one of claims 1-4, characterized in that the process is carried out in the dark 6. The method according to paragraphs f-5, characterized in that the process is carried out under pressure. .75 on PP. 1, 3, 4, 5 and 6; 10.29.76 on p.
    [2]
    2. Sources of information to be taken into account in the examination 1. E. Taylor R.,:
    [3]
    3. Chem Soc. 1962, p. 14811487.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU718008A3|1980-02-25|Method of producing isoquinoline derivatives
    US3819635A|1974-06-25|14-hydroxymorphinan derivatives
    US4085136A|1978-04-18|Optically-active 1-aryloxy-2-propanol intermediates of |-absolute configuration
    EP0071935B1|1985-11-13|1-phenyl-2-aminocarbonylindole compounds, process and intermediates for their preparation and medicines containing them
    US3378561A|1968-04-16|1-beta-arylthioethyltetrahydro-isoquinolines
    SU598557A3|1978-03-15|Method of preparing 1-phenoxy-3-aminopropane-2-ol derivatives or salts thereof
    US2251287A|1941-08-05|Substituted cinnamic acid esters and amides
    US3855227A|1974-12-17|-di-o-isopropylidene-2-keto-l-gulonates
    US3341528A|1967-09-12|Substituted benzoquinolines
    US4013666A|1977-03-22|-8-CARBOCYCLIC/CARBOCYCLIC METHYL-5,8,13,13A-TETRAHYDRO-2,3,10,11-TETRAMETHOXY-6H-dibenzo[a,g]quinolizines and intermediates thereto
    SU727140A3|1980-04-05|Method of preparing 14-hydroxymorphinane derivatives
    US4408063A|1983-10-04|Preparation of epihalohydrin enantiomers
    Dyke et al.1978|Pavinane and isopavinane alkaloids: Correlation of absolute configurations by synthesis
    KR960012371B1|1996-09-20|New 5-methoxy alkyl ammonium tetrahydrofurans
    US3324139A|1967-06-06|3-|-1-phenacylpiperidine compounds
    US3217007A|1965-11-09|Halo- and nitro-substituted phenethyl-z-methyl tetrahydroisoquinolsnes
    US4182911A|1980-01-08|Optically-active 1-aryloxy-2-propanol intermediates of |-absolute configuration
    US3317541A|1967-05-02|Decahydroisoquinoline esters of substituted benzoic acid and methods for their preparation
    DE69818988T2|2004-07-29|9,10-DIAZATRYCLO [4.2.11 2,5] DECAN- AND 9,10-DIAZATRICYCLO [3.3.1.1 2,6] DECANDERIVE WITH ANALGETIC EFFECT
    Nozaki et al.1968|Addition of carbethoxynitrene to trans-and cis-propenylbenzene and the ring-opening of the resulting aziridines
    DE1191380B|1965-04-22|Process for the preparation of piperazinoalkyl-iminodibenzylene
    SU1329620A3|1987-08-07|Method of producing isoquinoline or pharmaceutically acceptable additive acid salts thereof
    US3322778A|1967-05-30|Novel ether derivatives of benzmorphans
    Achini et al.1975|Synthesis of pyrrolidines by intramolecular carbanionic epoxide opening
    DE2336559A1|1974-01-31|4A-ARYL-TRANS-DECAHYDROCHINOLINES AND THE METHOD FOR THEIR PRODUCTION
    同族专利:
    公开号 | 公开日
    FI61485B|1982-04-30|
    MY8500287A|1985-12-31|
    IT8048000D0|1980-02-25|
    FI61485C|1982-08-10|
    LU76355A1|1977-06-24|
    DK553676A|1977-06-11|
    DD128320A5|1977-11-09|
    AT365579B|1982-01-25|
    AU2037576A|1978-06-15|
    SE7613824L|1977-06-11|
    CA1075241A|1980-04-08|
    DE2655883A1|1977-06-23|
    FI763543A|1977-06-11|
    DK149751B|1986-09-22|
    NZ182847A|1979-06-08|
    ATA908476A|1981-06-15|
    AU506657B2|1980-01-17|
    KE3361A|1984-02-17|
    SE434154B|1984-07-09|
    DK149751C|1987-03-23|
    CH625223A5|1981-09-15|
    FR2334359B1|1981-10-16|
    IL51074D0|1977-02-28|
    IL51074A|1980-05-30|
    US4179507A|1979-12-18|
    JPS5277069A|1977-06-29|
    IE44569L|1977-06-10|
    NL7613695A|1977-06-14|
    DE2655883C2|1990-02-01|
    IE44569B1|1982-01-13|
    FR2334359A1|1977-07-08|
    HK35084A|1984-04-27|
    JPS6043342B2|1985-09-27|
    IT1188908B|1988-01-28|
    MC1119A1|1977-08-12|
    NL178688B|1985-12-02|
    CY1217A|1984-04-06|
    NL178688C|1986-05-01|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3004031A|1958-07-03|1961-10-10|Allen & Hauburys Ltd|Diquaternary salts of papaverino esters|
    GB1125619A|1965-11-15|1968-08-28|Wellcome Found|Derivatives of bis-isoquinolines|US4235906A|1978-07-21|1980-11-25|Massachusetts General Hospital|Bis-isoquinolinium compounds, compositions and methods of use|
    CA1125287A|1978-07-21|1982-06-08|John J. Savarese|Bis isoquinolinium compositions and methods of use|
    US4491665A|1979-10-19|1985-01-01|Burroughs Wellcome Co.|Method of preparing isomers of bis isoquinolinium compounds|
    US4315935A|1980-04-14|1982-02-16|Smithkline Corporation|N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use|
    US4317826A|1980-05-27|1982-03-02|Smithkline Corporation|N,N'-Bis[substituted-1,2,3,4 tetrahydroisoquinolyl]disulfonylimides and antiallergic compositions and method of use|
    US4701460A|1980-12-17|1987-10-20|Burroughs Wellcome Co.|Long duration neuromuscular blocking agents|
    GB8418303D0|1984-07-18|1984-08-22|Wellcome Found|Compounds|
    GB9015473D0|1990-07-13|1990-08-29|Wellcome Found|Neuromuscular blocking agents|
    US5453510A|1990-07-13|1995-09-26|Burroughs Wellcome Co.|Neuromuscular blocking agents|
    US5240939A|1991-10-31|1993-08-31|Anaquest, Inc.|Nitrogen bridge tetrahydroisoquinolines|
    US5510355A|1994-09-06|1996-04-23|Bencherif; Merouane|Depolarizing skeletal muscle relaxants|
    IT1277700B1|1995-12-22|1997-11-11|Poli Ind Chimica Spa|PREPARATION PROCESS OF 2-BETA, 16-BETA-DIAMINO 3-ALPHA, 17-BETA- DIACYLOSSES 5-ALPHANDROSTANI, STRUCTURAL NEUROMUSCULAR BLOCKS|
    US5684154A|1996-02-16|1997-11-04|Abbott Laboratories|Process for the preparation and isolation of atracurium besylate|
    AU6730598A|1997-03-25|1998-10-20|Cornell Research Foundation Inc.|Substituted isoquinolines as ultra short acting neuromuscular block ers|
    GB0204087D0|2002-02-21|2002-04-10|Legislator 1563 Ltd|Di-ester derivatives as short acting neuromuscular blockers|
    JP5213137B2|2006-12-06|2013-06-19|コーネルリサーチファウンデーション，インコーポレイテッド|Medium duration neuromuscular blockers and antagonists thereof|
    US8461338B2|2007-03-08|2013-06-11|Chemagis Ltd.|-atracurium salts separation process|
    WO2008117271A1|2007-03-26|2008-10-02|Chemagis Ltd.|-atracurium salts separation process|
    WO2008132746A1|2007-05-01|2008-11-06|Chemagis Ltd.|Novel isoquinolinium compounds useful in the preparation of cisatracurium and associated intermediates|
    EP2155684B1|2007-05-01|2014-04-09|Chemagis Ltd.|Process for producing cisatracurium compounds and associated intermediates|
    WO2008155752A1|2007-06-18|2008-12-24|Chemagis Ltd.|-atracurium salts separation process|
    CN101337936B|2007-07-06|2011-03-23|江苏恒瑞医药股份有限公司|Method for purifying atracurium besylate by column chromatography|
    CN101337935B|2007-07-06|2011-01-12|江苏恒瑞医药股份有限公司|Method for purifying atracurium besylate by two-phase extraction|
    CA2692636A1|2007-07-09|2009-01-15|Chemagis Ltd.|Process for producing cisatracurium and associated intermediates|
    BRPI0816519A2|2007-10-29|2015-03-24|Chemagis Ltd|Process for preparing an isomerically enriched r, r'-atracurium salt and r, r'-atracurium salt|
    EP2283005A4|2008-05-01|2011-08-31|Chemagis Ltd|Cisatracurium derivatives, preparation and uses thereof|
    WO2011022491A1|2009-08-19|2011-02-24|Cornell University|Cysteine for physiological injection|
    WO2010107488A1|2009-03-17|2010-09-23|Cornell University|Reversible nondepolarizing neuromuscular blockade agents and methods for their use|
    ES2535326T3|2009-04-14|2015-05-08|Glaxo Group Limited|Preparation procedure for a biphenyl-2-ylcarbamic acid ester|
    EP2514754B1|2011-04-08|2013-08-21|King Saud University|6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical composition containing the same as neuromuscular blocker or skeletal muscle relaxant, and method for the preparation|
    CN102249998B|2011-06-20|2013-09-25|浙江仙琚制药股份有限公司|Method for preparing cisatracurium besylate|
    CN102898370A|2012-11-11|2013-01-30|苏州二叶制药有限公司|Cis-atracurium besilate for injection|
    WO2018193463A1|2017-04-21|2018-10-25|Neon Laboratories Limited|An improved process for the preparation of tetrahydroisoquinoline compounds|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB5058975|1975-12-10|
    GB4502876A|GB1579822A|1976-10-29|1976-10-29|Tetrahydroisoquinolinium muscle relaxants|
    [返回顶部]